PURE seeks USDA permission to begin in-plant poultry trials

By Joseph James Whitworth contact

- Last updated on GMT

©iStock/roibu
©iStock/roibu
PURE Bioscience has been backed by the US Food and Drug Administration (FDA) to trial higher concentrations of its antimicrobial to reduce Salmonella and Campylobacter.

The creator of the silver dihydrogen citrate (SDC) antimicrobial received a Preliminary Notification (PNC) authorization letter to do the in-plant poultry processing trials.

Technology is based on patented stabilized ionic silver and offers 24-hour residual protection as well as it being possible to formulate with other compounds.

PURE has submitted the PNC to the USDA seeking permission to begin poultry plant trials using up to 200 PPM of PURE Control.

The pending trials (estimated to begin end of Q1 with results before the end of Q2) will evaluate PURE Control applied as a spray to whole chicken carcasses during Online Reprocessing and Offline Reprocessing.

Hank Lambert, CEO, said: “As soon as we complete the regulatory process to gain approvals for use of SDC throughout poultry processing, we are poised to begin commercialization into this important new market.

“We already have strong interest from major poultry processors in our PURE Control solution to help meet stricter USDA standards for Salmonella control, replace current highly toxic interventions and protect their customers and brand.

“Simultaneously, we have already begun commercializing PURE Control in the +$300m US fresh produce processing aid market - where we also anticipate generating significant market share - with first orders expected this calendar quarter.”

Related news

Show more

Related products

Related suppliers